secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001493152-26-015170
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma receives NYSE American delisting notice for low equity
------------------------------------------------------------------------

- Stockholders' equity was $4.83M as of Dec 31, 2025, below the $6M threshold for five years of losses.
- Company has until May 2, 2026 to submit a plan to regain compliance; cure period up to 18 months.
- Independent auditor included a going-concern paragraph in the 10-K for the year ended Dec 31, 2025.
- No immediate impact on listing; common stock continues trading on NYSE American pending review.
- If plan is rejected, delisting proceedings will commence; company may appeal per NYSE rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315226015170/0001493152-26-015170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315226015170/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-015170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer